Five Prime Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2002)
Status: Acquired by Amgen (2021)

Organization Overview

First Clinical Trial
2008
NCT00687505
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Five Prime Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Endometrial Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 1)

Giant Cell Tumor of Tendon Sheath (Phase 2)

Giant Cell Tumors (Phase 2)

Glioma (Phase 1)

Neoplasms (Phase 1)

Stomach Neoplasms (Phase 3)

Synovitis (Phase 2)

Synovitis, Pigmented Villonodular (Phase 2)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 10